Bionik Laboratories Corp. (BNKL) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Bionik Laboratories Corp. (BNKL) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 62/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Bionik Laboratories Corp. (BNKL) Resumen de Asistencia Médica y Tuberías
Bionik Laboratories Corp. develops and commercializes robotic rehabilitation technologies, including the InMotion Robots suite. These technologies offer interactive therapy for patients with neurological and mobility impairments. The company operates within the medical care facilities sector, focusing on improving rehabilitation outcomes through advanced robotics.
Tesis de Inversión
Bionik Laboratories Corp. presents a speculative investment opportunity within the robotic rehabilitation technology sector. The company's InMotion Robots offer potential for improved patient outcomes and efficiency in physical therapy. However, with a market capitalization of $0.00B and negative profitability (Profit Margin: -274.0%), the company faces significant financial challenges. Key value drivers include the adoption of robotic rehabilitation technologies in healthcare and the expansion of the InMotion product line. Growth catalysts include potential partnerships with hospitals and rehabilitation centers and the development of new applications for the InMotion platform. Investors should carefully consider the company's financial position, competition, and regulatory landscape before investing.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Gross Margin of 54.8% suggests a strong pricing power for its rehabilitation technologies.
- Profit Margin of -274.0% highlights significant operational inefficiencies and the need for cost management.
- Beta of 9.36 indicates high volatility compared to the market, reflecting the speculative nature of the stock.
- No dividend is paid, which is typical for growth-stage companies reinvesting earnings.
Competidores y Pares
Fortalezas
- Proprietary InMotion Robots technology.
- Evidence-based rehabilitation protocols.
- Established relationships with hospitals and rehabilitation centers.
Debilidades
- Negative profitability.
- Limited financial resources.
- Small number of employees.
Catalizadores
- Upcoming: Potential partnerships with hospitals and rehabilitation centers to integrate InMotion Robots into rehabilitation programs.
- Ongoing: Expansion of the InMotion product line with new applications and specialized modules for different types of rehabilitation.
- Ongoing: Geographic expansion into new markets, such as Europe and Asia, to capitalize on growing demand for robotic rehabilitation technologies.
Riesgos
- Potential: Competition from other rehabilitation technology companies with greater financial resources and market share.
- Potential: Regulatory changes that could impact the approval and reimbursement of robotic rehabilitation technologies.
- Ongoing: Negative profitability and limited financial resources, which could hinder the company's ability to invest in R&D and marketing.
- Potential: Technological obsolescence if the company fails to keep pace with advancements in robotics and rehabilitation.
- Ongoing: Risks associated with trading on the OTC market, including limited liquidity and increased price volatility.
Oportunidades de crecimiento
- Expansion of InMotion Product Line: Bionik can expand its product line by developing new applications for the InMotion platform, such as specialized modules for different types of rehabilitation. The market for specialized rehabilitation technologies is growing, with a potential market size of $1 billion by 2028. This expansion can be achieved within the next 2-3 years through focused R&D efforts.
- Partnerships with Hospitals and Rehabilitation Centers: Bionik can establish partnerships with hospitals and rehabilitation centers to integrate the InMotion Robots into their existing rehabilitation programs. The market for rehabilitation equipment in hospitals and centers is estimated at $5 billion annually. These partnerships can be established within the next 1-2 years through targeted sales and marketing efforts.
- Geographic Expansion: Bionik can expand its geographic reach by entering new markets, such as Europe and Asia, where there is growing demand for robotic rehabilitation technologies. The global market for rehabilitation robots is projected to reach $2.7 billion by 2027. This expansion can be achieved within the next 3-5 years through strategic partnerships and distribution agreements.
- Development of Tele-Rehabilitation Solutions: Bionik can develop tele-rehabilitation solutions that allow patients to receive therapy remotely, expanding access to care and reducing costs. The market for tele-rehabilitation is growing rapidly, driven by advancements in technology and increasing demand for remote healthcare services. This development can be achieved within the next 1-2 years through investment in software and connectivity solutions.
- Integration with Virtual Reality (VR) and Augmented Reality (AR): Bionik can integrate VR and AR technologies into the InMotion platform to enhance the patient experience and improve outcomes. The market for VR/AR in healthcare is growing, with a potential market size of $4 billion by 2026. This integration can be achieved within the next 2-3 years through collaboration with VR/AR technology providers.
Oportunidades
- Expansion of InMotion product line.
- Partnerships with hospitals and rehabilitation centers.
- Geographic expansion.
Amenazas
- Competition from other rehabilitation technology companies.
- Regulatory changes.
- Technological obsolescence.
Ventajas competitivas
- Proprietary InMotion Robots technology.
- Evidence-based rehabilitation protocols.
- Established relationships with hospitals and rehabilitation centers.
Acerca de BNKL
Bionik Laboratories Corp., founded in 2010 and headquartered in Watertown, Massachusetts, is a robotics company dedicated to designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. The company's core offering is the InMotion Robots suite, which includes the InMotion ARM, InMotion ARM/HAND, and the InMotion Connect platform. The InMotion ARM is an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations, providing tailored therapy. The InMotion ARM/HAND supports therapy involving reaching with grasp and release movements, as well as individual hand movements. The InMotion Connect platform consists of a hardware device connected to the InMotion Robot, along with a subscription to InMotion Connect Pulse, enhancing data collection and therapy management. Bionik aims to improve patient outcomes in physical rehabilitation by leveraging advanced robotics and interactive technologies. The company operates primarily in the United States, serving hospitals, rehabilitation centers, and clinics.
Qué hacen
- Designs and develops physical rehabilitation technologies.
- Commercializes robotic products for rehabilitation.
- Offers InMotion Robots, a suite of robotic rehabilitation products.
- Provides InMotion ARM for interactive rehabilitation therapy.
- Offers InMotion ARM/HAND for therapy involving reaching and grasping movements.
- Provides InMotion Connect platform for data collection and therapy management.
Modelo de Negocio
- Sells InMotion Robots to hospitals, rehabilitation centers, and clinics.
- Generates revenue from subscriptions to the InMotion Connect Pulse platform.
- Provides maintenance and support services for InMotion Robots.
Contexto de la Industria
Bionik Laboratories Corp. operates in the medical care facilities industry, which is experiencing growth due to the aging population and increasing demand for rehabilitation services. The market for robotic rehabilitation technologies is expanding as healthcare providers seek to improve patient outcomes and reduce costs. Bionik competes with other companies offering rehabilitation robots and assistive devices. The industry is subject to regulatory oversight and technological advancements, requiring companies to innovate and adapt to changing market conditions.
Clientes Clave
- Hospitals
- Rehabilitation centers
- Clinics
Finanzas
Gráfico e información
Precio de la acción de Bionik Laboratories Corp. (BNKL): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BNKL.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BNKL.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BNKL.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BNKL en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Richard Paul Russo Jr.
Unknown
Information on Richard Paul Russo Jr.'s background is not available. His career history, education, and previous roles are unknown. Further research is needed to determine his qualifications and experience.
Historial: Information on Richard Paul Russo Jr.'s track record is not available. His key achievements, strategic decisions, and company milestones under his leadership are unknown. Further research is needed to assess his performance as CEO.
Información del mercado OTC de BNKL
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bionik Laboratories Corp. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and face greater regulatory scrutiny. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like NYSE or NASDAQ due to reduced transparency and liquidity.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure.
- Higher price volatility.
- Lower trading volume.
- Potential for fraud or manipulation.
- Increased regulatory scrutiny.
- Verify the company's financial statements.
- Research the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's regulatory filings.
- Evaluate the company's liquidity and trading volume.
- Consult with a financial advisor.
- Understand the risks associated with OTC investing.
- Company has been in operation since 2010.
- Focus on innovative robotic rehabilitation technologies.
- InMotion Robots product line with specific applications.
- Headquarters located in Watertown, Massachusetts.
- Presence in the healthcare sector.
Lo Que los Inversores Preguntan Sobre Bionik Laboratories Corp. (BNKL)
¿Cuáles son los factores clave para evaluar BNKL?
Bionik Laboratories Corp. (BNKL) actualmente tiene una puntuación IA de 62/100, indicando puntuación moderada. Fortaleza clave: Proprietary InMotion Robots technology.. Riesgo principal a monitorear: Potential: Competition from other rehabilitation technology companies with greater financial resources and market share.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BNKL?
BNKL actualmente puntúa 62/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BNKL?
Los precios de BNKL se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BNKL?
La cobertura de analistas para BNKL incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BNKL?
Las categorías de riesgo para BNKL incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from other rehabilitation technology companies with greater financial resources and market share.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BNKL?
La relación P/E para BNKL compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BNKL sobrevalorada o infravalorada?
Determinar si Bionik Laboratories Corp. (BNKL) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BNKL?
Bionik Laboratories Corp. (BNKL) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information on CEO background and track record is limited.
- AI analysis is pending, so analyst opinions are unavailable.
- OTC market data may be less reliable than major exchange data.